Compounds for the treatment of cns disorders

A method for the treatment of a disease that is accessible by the inhibition of PDE9 comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I)

• wherein
• Hc is tetrahydropyranyl,
• wherein one or more carbon ring atom(s) thereof optionally may be substituted by one or by two substituents independently selected from the group of fluorine, NC—, F3C—, HF2C—, FH2C—, F3C—CH2—, C1-6-alkyl-, C1-6-alkyl-O— and up to one carbon ring atom may be substituted with oxo;
• R1 is the group
• V—W—*
• wherein
• W is phenyl;
• V is selected from the group of phenyl or heteroaryl, said heteroaryl being selected from the group of oxadiazolyl, triazolyl, pyrazolyl, pyrrolyl, furanyl, pyridyl, pyrimidyl and pyridazinyl;
• —* is the binding point by which W is attached to the CR2R3 group in formula (I);
• wherein W and V independently of each other optionally may be substituted by one or more substituents selected from the group of fluorine, chlorine, bromine, C1-6-alkyl-, F3C—, HF2C—, FH2C—, F3C—CH2—, F3C—O—, HF2C—O—, C3-7-heterocycloalkyl-, H—O—C1-6-alkyl-, C1-6-alkyl-O—C1-6-alkyl-, C3-7-cycloalkyl-O—C1-6-alkyl-, C3-7-cycloalkyl-C1-3-alkyl-O—C1-6-alkyl-, phenyl-O—C1-6-alkyl-, benzyl-O—C1-6-alkyl-, H—O—, C1-6-alkyl-O—, C3-7-cycloalkyl-O—, C3-7-cycloalkyl-C1-3-alkyl-O—, phenyl-O—, benzyl-O—, N-morpholinyl, and NC—;
• R2 is selected from the group of H—, fluorine, F3C—, HF2C—, FH2C—, and C1-3-alkyl;
• and
• R3 is selected from the group of H—, fluorine, F3C—, HF2C—, FH2C—, and C1-3-alkyl;
• or a salt thereof.